Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

tation, and 3 were EGFR wild-type.

-- All 6 patients with EGFR-activating mutations demonstrated clinical

benefit (5 PR, 1 SD).

-- XL647 is generally well tolerated in this patient population. The most

frequently reported adverse events assessed as being related to XL647

were diarrhea, rash, fatigue, and nausea, all of which were Grade 1 or

Grade 2 in severity.

"The data reported today demonstrate that XL647 has potential utility in patient populations with both mutated and wild-type EGFR," said Dr. Shirish Gadgeel of Karmanos Cancer Institute at Wayne State University. "Importantly, the data highlight that patients to date appear to have milder EGFR-related side-effects -- rash and diarrhea -- than previously described with other EGFR inhibitors while retaining potent anti-tumor activity with durable responses and stable disease. Although these are early results, they provide a compelling rationale for expediting the full development of XL647 in non-small cell lung cancer."

"These data suggest that XL647 has the potential for utility in patients with NSCLC who have an activating EGFR mutation and those with wild-type EGFRs. We believe these data support an aggressive clinical development strategy in first, second and third-line treatment as both a single agent and in combination with other therapies," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Moreover, new data from an ongoing phase 1 trial of XL647 suggest that daily dosing results in higher drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for the late-stage development of XL647."

The most frequently reported treatment-related adverse events (AEs) were Grade 1 and 2 diarrhea and fatigue, and Grade 1 nausea and rash. Six pat
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Calif. , May 27, 2015  Two years ... biotech professionals, hackers and citizen scientists, Oakland ... $30,000 crowdfunding campaign promoting its mission to democratize science ... Temescal District. ... Based out of ...
(Date:5/27/2015)... ­ Caris Life Sciences®, a leading biotechnology ... today announced it has appointed the Levine Cancer Institute, ... site in the Caris Centers of Excellence for Precision ... is one of the largest cancer care providers throughout ... patients annually. Derek Raghavan , M.D., Ph.D., President ...
(Date:5/26/2015)... CITY , Kalifornien und HILDEN, Deutschland, ... QIAGEN Clinical Insight ® ... von Genvarianten und die Erstellung dazugehöriger Berichte; ... ESHG     QIAGEN N.V. (NASDAQ: ... gab heute die Markteinführung von QIAGEN Clinical ...
(Date:5/26/2015)... China , May 26, 2015 Tianyin ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), announced that the Company,s Annual Meeting of Shareholders ... scheduled to be held at the Company,s office located ... conference call, at 9:00 AM (local time in ...
Breaking Biology Technology:East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3
... BVF Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology Value ... to purchase all of the outstanding shares of Avigen, Inc. ... announced today that it has extended the expiration date for ... on Friday, March 6, 2009. The tender offer was previously ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... ( http://www.cordblood-america.com ) focused on bringing the life ... and internationally, today announced that Matthew Schissler, founder ... Gaskins, provided details of the Company,s special shareholder ...
... Declares 341st Consecutive Quarterly Dividend ABBOTT PARK, Ill., Feb. ... ABT ) today increased the company,s quarterly common dividend 11 ... consecutive year that Abbott has increased its dividend payout and ... since 1924. The cash dividend is payable May 15, ...
Cached Biology Technology:BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009 2BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009 3In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting 2
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... plants to build new organs throughout their whole life. ... factors work together to prevent plants from having growth ... from the Max Planck Institute for Developmental Biology have ... and a regulatory protein, which controls the number of ...
... flu did you get? TIGR scientists survey five New York ... season, scientists at The Institute for Genomic Research (TIGR) have ... this week's journal Nature , the researchers report the ... offers a unique snapshot of the rapidly evolving flu virus ...
... infected with HIV in the UK have one of the ... the world, prompting fears of a second wave epidemic of ... , The study authors are concerned that the large reductions ... were given combinations of drugs (combination antiretroviral therapy) may be ...
Cached Biology News:Max Planck researchers make a breakthrough in plant stem cell research 2Max Planck researchers make a breakthrough in plant stem cell research 3First big influenza genome study reveals flu evolution 2First big influenza genome study reveals flu evolution 3First big influenza genome study reveals flu evolution 4HIV drug resistance increasing in UK and among highest in the world 2
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
... 4 deuterium atoms at the 3, 3', ... for use as an internal standard for ... GC- or LC-mass spectrometry. PGE2 is one ... acid and one of the most widely ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Request Info...
Biology Products: